GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Current Accrued Expense

Nanopharmaceutics (Nanopharmaceutics) Current Accrued Expense : $0.00 Mil (As of Sep. 2018)


View and export this data going back to 2016. Start your Free Trial

What is Nanopharmaceutics Current Accrued Expense?

Nanopharmaceutics's Current Accrued Expense for the quarter that ended in Sep. 2018 was $0.00 Mil.

Nanopharmaceutics's annual Current Accrued Expense increased from Dec. 2015 ($0.00 Mil) to Dec. 2016 ($0.09 Mil) and increased from Dec. 2016 ($0.09 Mil) to Dec. 2017 ($0.11 Mil).


Nanopharmaceutics Current Accrued Expense Historical Data

The historical data trend for Nanopharmaceutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanopharmaceutics Current Accrued Expense Chart

Nanopharmaceutics Annual Data
Trend Dec15 Dec16 Dec17
Current Accrued Expense
- 0.09 0.11

Nanopharmaceutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 0.11 - - -

Nanopharmaceutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Nanopharmaceutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Nanopharmaceutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanopharmaceutics (Nanopharmaceutics) Business Description

Traded in Other Exchanges
N/A
Address
14120 NW 126 Terrace, Alachua, FL, USA, 32615
Nanopharmaceutics Inc is a clinical-stage specialty pharmaceutical company. It is engaged in developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company's pipeline products include Triapine, Ammonium Tetrathiomolybdate, and Aza-TdC targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3 targeting CNS; and Ramoplanin and NanoDOX.